154 related articles for article (PubMed ID: 3930806)
21. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
[TBL] [Abstract][Full Text] [Related]
22. [In vitro antibacterial activity of various cephems against clinical isolates from complicated urinary tract infections].
Kamidono S; Fujii A; Arakawa S; Kataoka N; Ishigami J
Jpn J Antibiot; 1985 Jan; 38(1):179-89. PubMed ID: 3989977
[TBL] [Abstract][Full Text] [Related]
23. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1983). III. Secular changes in susceptibility].
Kosakai N; Igari J; Kumamoto Y; Sakai S; Shigeta S; Shiraiwa Y; Abe K; Tazaki H; Iri H; Uchida H
Jpn J Antibiot; 1985 Aug; 38(8):2243-312. PubMed ID: 3935824
[TBL] [Abstract][Full Text] [Related]
24. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
[TBL] [Abstract][Full Text] [Related]
25. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
[TBL] [Abstract][Full Text] [Related]
26. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
[TBL] [Abstract][Full Text] [Related]
27. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
[TBL] [Abstract][Full Text] [Related]
28. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
29. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
[TBL] [Abstract][Full Text] [Related]
31. [Susceptibility of clinical isolates to aztreonam].
Nagasawa Z; Nishimura T; Nagumo F; Ueda H; Tadano J; Katoh O; Yamada H
Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
[TBL] [Abstract][Full Text] [Related]
32. Ofloxacin: in-vitro activity against clinical isolates.
Grima P
Chemioterapia; 1985 Dec; 4(6):434-5. PubMed ID: 3938347
[TBL] [Abstract][Full Text] [Related]
33. [Susceptibilities of clinical isolates to aminoglycoside antibiotics. Susceptibility of clinical isolates from patients with complex and refractory infections].
Deguchi K
Jpn J Antibiot; 1982 Aug; 35(8):1977-86. PubMed ID: 7154245
[TBL] [Abstract][Full Text] [Related]
34. In-vitro activity of norfloxacin against Enterobacteriaceae and Pseudomonas aeruginosa.
García-Rodríguez JA; Gómez-García AC; Rodrigo N
J Antimicrob Chemother; 1984 Aug; 14(2):192-3. PubMed ID: 6238928
[No Abstract] [Full Text] [Related]
35. [Current status of aminoglycoside resistance in hospital Enterobacteriaceae].
Ronco E; Migueres ML; Vacheron F; Guenounou M
Pathol Biol (Paris); 1988 May; 36(5):430-4. PubMed ID: 3043339
[TBL] [Abstract][Full Text] [Related]
36. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
[TBL] [Abstract][Full Text] [Related]
37. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
Sader HS; Castanheira M; Farrell DJ; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
Weinstein RA; Nathan C; Delzell D; Kabins SA
Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
[TBL] [Abstract][Full Text] [Related]
39. [Antibacterial activities of ofloxacin against recent isolates from patients with community-acquired infections].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
Jpn J Antibiot; 1991 Sep; 44(9):941-57. PubMed ID: 1960856
[TBL] [Abstract][Full Text] [Related]
40. [Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase].
López-Yeste M; Xercavins M; Lite J; Cuchí E; Garau J
Enferm Infecc Microbiol Clin; 1996 Apr; 14(4):211-4. PubMed ID: 9044634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
